Evidence map›Paper›PMID 40085190›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response.

Samuel Slone, Sarah R Anthony, Lisa C Green, Sharon Parkins, Pooja Acharya, Daniel A Kasprovic, Kelsi Reynolds, Robert M Jaggers, Michelle L Nieman, Perwez Alam and 9 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  5. Review
  6. Article
  7. RNA binding proteins as mediators of pathological cardiac remodeling.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Samuel SloneDivision of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-5073-9722
Sarah R AnthonyDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-6230-8188
Lisa C GreenDivision of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-1164-6611
Sharon ParkinsDivision of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0003-2279-1598
Pooja AcharyaDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-1877-6013
Daniel A KasprovicDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0009-0004-1350-3755
Kelsi ReynoldsPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.ORCID https://orcid.org/0009-0001-8201-7644
Robert M JaggersDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0001-9613-7359
Michelle L NiemanDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0001-8504-6697
Perwez AlamDepartment of Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA.ORCID https://orcid.org/0000-0002-7229-8008
Xiaoqing WuDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.ORCID https://orcid.org/0000-0003-2076-4107
Sudeshna RoyDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-0237-4156
Jeffrey AubéDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-1049-5767
Liang XuDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.ORCID https://orcid.org/0000-0001-9196-4232
Zihai LiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-4603-927X
John N LorenzDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0003-2161-9833
A Phillip OwensDivision of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-0835-620X
Onur KanisicakDorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-8393-4874
Michael TranterDepartment of Molecular Medicine and Therapeutics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-0609-3717

Funding

Understanding Cardiovascular Disease MechanismsT32HL125204 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Evangelia G Kranias, Jeffery D Molkentin · 2015 to 2026
$3.4M
Post-transcriptional control of adipose tissue gene expression as an endocrine mediator of cardiac pathologyR01HL158671 · NHLBI · UNIVERSITY OF CINCINNATI · PI Michael Tranter · 2022 to 2026
$3.1M
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted TherapyR01CA243445 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI DIXON, DAN ALAN, XU, LIANG · 2019 to 2023
$3.0M
Functional and mechanistic delineation of HuR-Wisp1 signaling on myofibroblast activityR01HL166326 · NHLBI · UNIVERSITY OF CINCINNATI · PI Onur Kanisicak, Michael Tranter · 2023 to 2026
$2.6M
Molecular cancer therapy targeting HuR-ARE interactionR01CA191785 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY, XU, LIANG · 2015 to 2019
$2.1M
Regulators of extracellular matrix production during cardiac development and diseaseR01HL148598 · NHLBI · UNIVERSITY OF CINCINNATI · PI KANISICAK, ONUR · 2020 to 2024
$2.0M
Investigation of Human Antigen R (HuR) as a Novel Mediator of Cardiac HypertrophyR01HL132111 · NHLBI · UNIVERSITY OF CINCINNATI · PI TRANTER, MICHAEL · 2016 to 2020
$1.8M
Integrative Functional Profiling of Tumor-Derived Extracellular VesiclesR33CA252158 · NCI · UNIVERSITY OF FLORIDA · PI XU, LIANG, ZENG, YONG · 2021 to 2024
$1.0M
HuR-Wisp1 signaling in cardiac fibroblastsF31HL170636 · NHLBI · UNIVERSITY OF CINCINNATI · PI PARKINS, SHARON · 2023 to 2024
$97k
American Heart Association (AHA) 1029875American Heart Association (AHA) CDA34110117American Heart Association (AHA) PRE35210795American Heart Association (AHA) PRE35230020American Heart Association-American Stroke Association 18CDA34110117American Heart Association Career Development Grant 23CDA1052132American Heart Association Postdoctoral Fellowship 20POST35200267HHS | NIH | National Cancer Institute (NCI) CA191785HHS | NIH | National Cancer Institute (NCI) CA243445HHS | NIH | National Cancer Institute (NCI) CA252158HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) F31-HL170636HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL125204HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL132111HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL148598HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL166326NCI NIH HHS R01 CA191785NCI NIH HHS R01 CA243445NCI NIH HHS R33 CA252158NHLBI NIH HHS F31 HL170636NHLBI NIH HHS R01 HL132111NHLBI NIH HHS R01 HL148598NHLBI NIH HHS R01 HL158671NHLBI NIH HHS R01 HL166326NHLBI NIH HHS T32 HL125204
6 · The paper itself

Abstract

The RNA-binding protein human antigen R (HuR) has been shown to reduce cardiac remodeling following both myocardial infarction and cardiac pressure overload, but the full extent of the HuR-dependent mechanisms within cells of the myocardium has yet to be elucidated. Wild-type mice were subjected to 30 min of cardiac ischemia (via LAD occlusion) and treated with a novel small molecule inhibitor of HuR at the time of reperfusion, followed by direct in vivo assessment of cardiac structure and function. Direct assessment of HuR-dependent mechanisms was done in vitro using neonatal rat ventricular myocytes (NRVMs) and bone marrow-derived macrophages (BMDMs). HuR activity is increased within 2 h after ischemia/reperfusion (I/R) and is necessary for early post-I/R inflammatory gene expression in the myocardium. Despite an early reduction in inflammatory gene expression, HuR inhibition has no effect on initial infarct size at 24 h post-I/R. However, pathological remodeling is reduced with preserved cardiac function at 2 weeks post-I/R upon HuR inhibition. RNA sequencing analysis of gene expression in NRVMs treated with LPS to model damage-associated molecular pattern (DAMP)-mediated activation of toll-like receptors (TLRs) demonstrates a HuR-dependent regulation of pro-inflammatory chemokine and cytokine gene expression in cardiomyocytes. Importantly, we show that conditioned media transfer from NRVMs pre-treated with HuR inhibitor loses the ability to induce inflammatory gene expression and M1-like polarization in bone marrow-derived macrophages (BMDMs) compared to NRVMs treated with LPS alone. Functionally, HuR inhibition reduces macrophage infiltration to the post-ischemic myocardium in vivo. Additionally, we show that LPS-treated NRVMs induce the migration of peripheral blood monocytes in a HuR-dependent endocrine manner. These studies demonstrate that HuR is necessary for early pro-inflammatory gene expression in cardiomyocytes following I/R injury that subsequently mediates monocyte recruitment and macrophage activation in the post-ischemic myocardium.

Indexed as

ELAV-Like Protein 1Gene Expression RegulationImmunity, InnateInflammationMyocardial IschemiaMyocardial Reperfusion InjuryMyocytes, CardiacVentricular RemodelingAnimalsMacrophagesMaleMiceMice, Inbred C57BLMyocardial InfarctionRatsRats, Sprague-DawleyElavl1 protein, mouseELAV-Like Protein 1cardiac remodelingheartHuRinflammationinnate immune responseischemia/reperfusion injury

Identifiers

PMID40085190
PMCPMC11908633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.